Pulsatile GnRH Therapy for Cognitive Decline With Olfactory Dysfunction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cognitive disorders associated with olfactory dysfunction, such as Alzheimer's disease and Down syndrome, are inadequate, and there is a need for novel therapeutic approaches that address the underlying pathological pathways involving gonadotropin-releasing hormone (GnRH) deficiency.
Innovation Solution
Administering GnRH in a pulsatile manner to restore normal GnRH secretion patterns, which can be achieved through transdermal or parenteral administration using pumps or grafting GnRH-producing neurons, and regulating GnRH expression via microRNA-200 and miR-155 overexpression to reverse olfactory and cognitive impairments.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If GnRH is administered continuously, then the treatment is simple to implement, but it fails to restore normal GnRH secretion patterns and does not effectively reverse cognitive impairments
Solution Approach 1:
The patent applies periodic action by administering GnRH in pulsatile manner rather than continuously. The pump delivers GnRH at intervals of 90-120 minutes, mimicking the natural pulsatile secretion pattern of GnRH neurons. This periodic administration restores normal hypothalamic-pituitary-gonadal axis function and effectively reverses cognitive impairments in Down syndrome patients, resolving the contradiction between simplicity and effectiveness.
2Reliability
If GnRH administration frequency is increased to better mimic natural secretion, then cognitive improvement is enhanced, but the device complexity increases
Solution Approach 1:
The patent employs a portable automated pump that operates independently once programmed. The device automatically delivers GnRH pulses at predetermined intervals without requiring continuous human intervention or monitoring. This self-service capability reduces operational complexity while maintaining the therapeutic benefits of pulsatile administration with 90-120 minute intervals.
3Reliability
If GnRH is administered to restore normal secretion patterns, then olfactory and cognitive impairments are reversed, but the treatment approach becomes more complex
Solution Approach 1:
The patent utilizes periodic action through pulsatile GnRH administration every 90-120 minutes, which effectively reverses olfactory and cognitive impairments associated with Down syndrome by restoring normal GnRH secretion patterns. This approach balances therapeutic effectiveness with manageable device complexity through automation.
Solution Approach 2:
The automated portable pump provides self-service functionality by automatically administering GnRH pulses according to pre-programmed intervals without requiring continuous medical supervision. This reduces the operational complexity of the treatment system while maintaining the therapeutic benefits of pulsatile administration.
Data Source
Figure 1A
Figure 1B~1D
Figure 1E~1G
AI summary
The present invention pertains to novel therapeutic ways for treating cognitive disorders associated with olfactory dysfunction. By using a mouse model of Down syndrome (DS - Ts65Dn mice), the present inventors have demonstrated that GnRH insufficiency is involved in the age-dependent acquisition of cognitive decline in DS and that pulsatile GnRH treatment allows reversing olfactory- and cognitive-associated impairments in DS. The present inventors have further demonstrated that GnRH insufficiency is involved in the pathological pathways of cognitive disorders in which the cognitive decline is associated with olfactory dysfunction, and, accordingly, that pulsatile GnRH administration can be used for the treatment of cognitive disorders associated with olfactory dysfunction. Accordingly, the present invention pertains to the use of GnRH for the treatment of cognitive disorders, said GnRH being administered by pulsatile administration. The present invention further pertains to a miR-200 and/or a miR-155, which are known to be involved in GnRH-secretion regulation, for use in the treatment of cognitive disorders.